Reviva Pharmaceuticals Reports Reduced Net Losses and Strategic Funding Developments for Q3 2025

Reviva Pharmaceuticals Holdings, Inc. reported its financial results for the third quarter and nine months ended September 30, 2025, revealing a net loss of $4.0 million for the quarter, a significant reduction from the $8.4 million loss recorded in the same period last year. For the nine-month period, the company reported a net loss of $16.5 million, down from $23.7 million in the prior year. The decrease in losses is attributed to a substantial reduction in operating expenses, which totaled $4.0 million for the third quarter, compared to $8.5 million in the same quarter of 2024. This reduction was primarily driven by lower research and development costs, which fell to $2.1 million from $6.9 million year-over-year.

Reviva's total assets decreased to $14.3 million as of September 30, 2025, down from $15.5 million at the end of 2024. The company's cash and cash equivalents also saw a slight decline, totaling $13.2 million compared to $13.5 million at the end of the previous fiscal year. Notably, total current liabilities decreased significantly to $9.7 million from $14.6 million, primarily due to the repayment of short-term debt and a reduction in accrued clinical expenses. The company’s stockholders' equity increased to $4.5 million, up from $812,572 at the end of 2024, reflecting the issuance of common stock in public offerings.

In terms of strategic developments, Reviva completed two public offerings in 2025, raising approximately $17.4 million in gross proceeds from the June offering and $9.0 million from the September offering. These offerings included the issuance of common stock and warrants, which have been classified as equity instruments. The company also engaged in an at-the-market (ATM) offering program, generating additional funds. As of September 30, 2025, Reviva had 96.3 million shares of common stock outstanding, a significant increase from 46.6 million shares at the end of 2024.

Operationally, Reviva has focused on advancing its clinical trials and product development, which are critical to its long-term growth strategy. The company has incurred substantial expenses related to clinical trials, which are expected to continue as it seeks to bring its therapies to market. Reviva's management indicated that while the company has sufficient cash to cover anticipated expenses into the second quarter of 2026, it will need to secure additional funding to support ongoing operations and development efforts. The company is exploring various financing options, including public or private equity and debt financings, as well as potential collaborations.

Looking ahead, Reviva anticipates continued investment in research and development, which may lead to increased operating losses in the near term. The company acknowledges the need to generate significant revenues to achieve profitability, a goal that remains uncertain given the challenges inherent in the pharmaceutical industry. The management's outlook emphasizes the importance of securing additional funding to sustain operations and advance its clinical programs, while also addressing the substantial doubt regarding the company's ability to continue as a going concern within the next year.